@?Olanzapine, @?sertindole and schizophrenia

Drug and Therapeutics Bulletin

Volumn 35, Issue 11, 1997, Pages 81-83

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SERTINDOLE;

BODY WEIGHT DISORDER; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DELUSION; DROWSINESS; DRUG CONTRAINDICATION; DRUG RECEPTOR BINDING; DYSPNEA; EDEMA; HALLUCINATION; HUMAN; NEGATIVE SYNDROME; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARESTHESIA; QT INTERVAL; RATING SCALE; SCHIZOPHRENIA; SHORT SURVEY; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

EID: 0030829872     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.1997.351181     Document Type: Short Survey

References (17)

1. Tumer T. ABC of mental health. Schizophrenia. BMJ 1997; 315: 108-11.
2. The drug treatment of patients with schizophrenia. DTB 1995; 33: 81-6.
3. Risperidone and remoxipride for schizophrenia. DTB 1993; 31: 101-2.
4. Clozapine and loxapine for schizophrenia. DTB 1991; 29: 41-2.
5. Gerlach J, Peacock L. Intolerance to neuroleptic drugs: the art of avoiding extrapyramidal syndromes. Eur Psychiatry 1995; 10 (suppl 1): S27-31.
6. Reus VT, Olanzapine: a novel atypical neuroleptic agent. Lancet 1997; 349: 1264-5.
7. Tamminga CA, Mack RJ, Granneman GR, Silber CJ, Kashkin KB. Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 1997; 12 (suppl 1). S29-35.
8. 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology 1996; 124: 148-53.
9. Olanzapine. Summary of product characteristics, UK. Lilly, September 1996.
10. Beasley Jr CM, Tollefson G, Tran P et al. Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111-23.
11. Beasley Jr CM, Sanger T, Satterlee W et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996; 124: 159-67.
12. Beasley Jr CM, Hamilton SH, Crawford AM et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychophormacol 1997; 7: 125-37.
13. Tollefson GD, Beasley Jr CM, Tran PV et al. Olanzapine versus haloperidot in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457-65.
14. Tran PV, Hamilton SH, Kuntz AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407-18
15. Sertindole. Summary of product characteristics, UK. Lundbeck Limited, October 1996.
16. van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB and the Sertindole Study Group. A randomized, controlled, dose-ranging trial of Sertindole in patients with schizophrenia. Psychopharmacology 1996; 124: 168-75.
17. Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of Sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154: 782-91.